



November 9, 2020

✓ **BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**National Stock Exchange of India Ltd.,**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

Re: **Disclosure pursuant to Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Subject: U.S.FDA inspection of Lupin's Somerset (NJ, US) facility**

The Company's subsidiary Novel Laboratories Inc. based in Somerset, NJ has just concluded a U.S. FDA inspection. The inspection commenced on September 10, 2020 and concluded on November 5, 2020. The duration of the inspection was prolonged due to COVID-related delays and challenges.

The inspection at the Somerset, NJ facility closed with thirteen observations. We are confident of addressing these observations and will work closely with the agency to address their concerns.

The Company does not believe that this will have an impact on disruption of supplies or the existing revenues from operations of this facility. The facility contributes less than 5 percent of our global revenues.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For **LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS -11973)**